At today’s annual meeting of the American Society of Clinical Oncology (ASCO), researchers announced the results of a clinical trial of Nexavar. The drug, made by Bayer, was used in a clinical trial which was stopped early due to the overwhelmingly good response. The liver cancer patients who took Nexavar had 44% more time to live, than those that did not take the drug.

This is a significant development for those with cancer of the liver. Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, is quoted “This is going to change the standard of practice.”

Liver cancer is one of the most aggressive cancers and most patients often pass away within a year of diagnosis. It is the third most deadly cancer in the United States. Surgery, radiation, and chemotherapy treatments are all used to treat this deadly disease but, until now, there were no systemic treatments which work through the bloodstream.

Nexavar has already been approved in the United States as a treatment for advanced kidney cancer and is being studied for other cancers as well.

See the full article on MSN Health here.

You can read about it on here.

Bo Frith